The U.S. Food and Drug Administration (FDA) announced Jan. 24 it is restricting the use of two monoclonal antibody treatments for COVID-19, saying data show such treatments are “highly unlikely” to be active against the Omicron variant, currently the dominant strain in the country. Monoclonal antibodies are laboratory-created proteins that mimic natural antibodies the body…
Florida’s DeSantis Says Feds Backed Down on Limiting Monoclonals
Florida Gov. Ron DeSantis announced on Jan. 3 that the federal government had relaxed its policies on limiting monoclonal antibody treatment drugs, paving the way for the state to receive more doses. DeSantis said as soon as more doses were released he would be setting up to 10 new public infusion centers in southern and…
Florida’s DeSantis Says Feds Backing Down on Limiting Monoclonals
Florida Gov. Ron DeSantis announced on Jan. 3 that the federal government had relaxed its policies on limiting monoclonal antibody treatment drugs, paving the way for the state to receive more doses. DeSantis said as soon as more doses were released he would be setting up to 10 new public infusion centers in southern and…
What Do We Know About Omicron?
December 2, 2021
admin
AfricaArchivedBotswanaCCPCCP VirusCoronavirus In-Depthdelta variantDr. Scott GottliebInternationalModernaNaming the VirusNewsOmicron variantPfizerRegeneronSouth AfricaVaccines & SafetyWorld
0 Comment
It’s been just days since a new strain of COVID-19 made headlines across the planet. While the World Health Organization (WHO) has warned that the new Omicron variant presents a “very high risk,” other scientists, including some with WHO, have stressed that we still have much to learn about the new CCP (Chinese Communist Party)…
Regeneron Says Its COVID-19 Antibody Cocktail May Be Less Effective Against Omicron
Regeneron said on Nov. 30 that its COVID-19 antibody drug cocktail could lose effectiveness against Omicron, providing further indication that the arsenal of medical products developed to fight the disease may need modification to be effective against the new strain. The drugmaker said in a statement (pdf) that early tests show that the high number…
Regeneron Says Antibodies Show Success in Preventing COVID-19 Infections
Monoclonal antibodies that have already proven successful in preventing hospitalizations in people who contract COVID-19 may also serve as protection against COVID-19 infection, according to new data. Regeneron said its monoclonal antibody treatment reduced the risk of contracting the disease by 81.6 percent among uninfected persons. The data comes from a phase three trial run…
Texas Governor Abbott Tests Negative for COVID-19 After ‘Brief and Mild’ Infection
Texas Governor Greg Abbott, whose state is engulfed in a fourth COVID surge, said he tested negative for COVID-19 on Saturday after having a “brief and mild” bout with the infection this week. In video posted on Twitter, the Republican governor, whose office announced four days ago that he had tested positive for the virus…
Texas Gov. Abbott Tests Negative for COVID-19 After ‘Brief and Mild’ Infection
Texas Governor Greg Abbott, whose state is engulfed in a fourth COVID surge, said he tested negative for COVID-19 on Saturday after having a “brief and mild” bout with the infection this week. In video posted on Twitter, the Republican governor, whose office announced four days ago that he had tested positive for the virus…
Regeneron’s COVID-19 Antibody Treatment Authorized for Injection
Regeneron announced on Friday that the Food and Drug Administration (FDA) is allowing a lower dose of its CCP virus treatment for injection. The approval comes as an update to the FDA’s emergency use authorization (EUA) for the company’s antibody cocktail to treat COVID-19, the disease caused by the CCP (Chinese Communist Party) virus. The treatment has…
Regeneron to Seek FDA Approval for Its COVID-19 Antibody Cocktail to Be Used for Prevention
Regeneron Pharmaceuticals is pursuing FDA approval for its antibody cocktail to be used as a preventative treatment for COVID-19 after its latest study showed positive results. The company announced in a release that its phase three prevention trial for REGEN-COV—a combination of casirivimab and imdevimab—showed that the drug reduced the risk of symptomatic infections by…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`